35 bioequivalence tests approved in July

Published: 2012-08-09 06:57:00

Updated: 2012-08-09 06:57:00

The Korea Food and Drug Administration confirmed recently that it approved bioequivalence tests for a total of 35 drugs filed by of 20 pharmaceutical firms in July.

By company, LG Life Sciences topped the list with 9 generics – Atacand (candesartan), Diovan (valsartan), Olmetec (olmesartan), Coaprovel (hydrochlorothiazide), Micardis (telminsartan), Keppra (levetiracetam), Stoga (lafutidine) ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.